Megakaryocytic Expansion in Gilteritinib-Treated Acute Myeloid Leukemia Patients Is Associated With AXL Inhibition.
Megakaryocytic Expansion in Gilteritinib-Treated Acute Myeloid Leukemia Patients Is Associated With AXL Inhibition.
复制标题
DOI：
10.3389/fonc.2020.585151
复制
发表时间：
2020
影响因子：
4.7
通讯作者：
Ranheim EA
中科院分区：
文献类型：
--
作者：
Suknuntha K;Choi YJ;Jung HS;Majumder A;Shah S;Slukvin I;Ranheim EA
Numerous recurrent genetic mutations are known to occur in acute myeloid leukemia (AML). Among these common mutations, Fms-like tyrosine kinase 3 remains as one of the most frequently mutated genes in AML. We observed apparent marrow expansion of megakaryocytes in three out of six patients with Flt3-mutated AML following treatment with a recently FDA-approved Flt3 inhibitor, gilteritinib which possesses activity against internal tandem duplication and tyrosine kinase domain Flt3 mutations and also inhibits tyrosine kinase AXL. To assess whether biopsy findings can be attributed to promotion of megakaryocytic (Mk) differentiation with gilteritinib, we devised a cellular assay by overexpressing double mutated Flt3-ITDY591F/Y919F in chronic myeloid leukemia cell line K562 to study Mk differentiation in the presence of Flt3 and AXL inhibitors with non-mutually exclusive mechanisms. These experiments demonstrated the lack of direct effect Flt3 inhibitors gilteritinib and quizartinib on megakaryocytic differentiation at either transcriptional or phenotypic levels, and highlighted antileukemic effects of AXL receptor tyrosine kinase inhibitor and its potential role in megakaryocytic development.
登录
查看更多内容
影响因子：
20.3
作者：
Ben-Batalla, Isabel;Schultze, Alexander;Loges, Sonja
通讯作者：
Loges, Sonja
影响因子：
64.5
作者：
Adolfsson, J;Månsson, R;Jacobsen, SEW
通讯作者：
Jacobsen, SEW
影响因子：
4.8
作者：
Kazi, Julhash U.;Sun, Jianmin;Ronnstrand, Lars
通讯作者：
Ronnstrand, Lars
影响因子：
5.7
作者：
Larrosa-Garcia M;Baer MR
通讯作者：
Baer MR
影响因子：
20.3
作者：
Breitenbuecher, Frank;Schnittger, Susanne;Fischer, Thomas
通讯作者：
Fischer, Thomas